Mindset Pharma (MSET.C) announced that their in vivo (in an animal) testing carried out by InterVivo Solutions confirmed that the majority of their patent-pending compounds created effects that correlate…
Psychedelics
Nova Mentis Life Science (NOVA.C) announced they will be organising a North American autism spectrum disorder (ASD) data bank to support the development of psilocybin-based compounds in the diagnosis…
Core One Labs (COOL.C) inked a letter of intent to pick up pharmaceuticals company, Akome Biotech today, according to a press release. Akome develops psychedelic-based drugs to treat rare…
Sixth Wave Innovations (SIXW.C) entered into a non-binding letter of intent (LOI) with Halucenex Life Sciences, a soon to be wholly-owned subsidiary of Cresco Pharma. According to the terms…
Cybin (CYBN.NE) announced they are forming a Clinical Advisory Board, which will be chaired by Alex Belser, Cybin’s Chief Clinical Officer. The board will consist of Belser (PhD), Maurizio…
$13 million give or take Earlier this week the law firms of Wolf Haldenstein Adler Freeman & Herz and The Portnoy Law Firm both announced class-action lawsuits against psychedelics…
Mindset Pharma (MSET.C) announced they have completed their $7.5 million “bought deal” public offering. The offering issued 10,000,000 units sold at $0.75 each. Each unit granted the buyer one…
A study was published today in the New England Journal of Medicine which tested COMPASS Pathways’ (CMPS.Q) COMP360 psilocybin. The study is a phase II double-blind, randomized, controlled trial…
Cedar Clinical Research Novamind (NM.C) announced today it’s increasing its investment in the Australian-based drug company Bionomics (BNO.ASX). The company is focused primarily on anxiety, PTSD, and central nervous…
It’s 2031, COVID is long gone. Jose Conseco is president of the USA. Jeff Bezos redesigns the human digestive system to not need food or water Peter Thiel spends…